Morphic Therapeutic stock nosedives on disappointing trial data


With two Big Pharmas abandoning partnerships and its only clinical-stage drug posting less-than-encouraging data, Waltham's Morphic Therapeutic has had a rough couple of years.

Previous Judge rejects, rewrites summary for Missouri abortion initiative petition
Next Regions Bank inks first jersey sponsorship deal with Nashville Predators